Physician profile
Charles Mayes
NPI 1811916414
$4,400.47
in general payments reported to CMS, 2019-2025
21 companies · $1,004 in 2025
The $1,004 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $144 · 2021: $166 · 2022: $174 · 2023: $79.77 · 2024: $2,443 · 2025: $1,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,228 · Travel and Lodging: $1,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,228.34 |
| Travel and Lodging | $1,298.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,720.15 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Micra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $261.93 | 2024-2025 | Lifevest |
| Abiomed | $220.10 | 2019-2024 | Impella |
| Novartis Pharmaceuticals Corporation | $177.79 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $157.90 | 2019-2025 | Camzyos, Eliquis |
| Medtronic Vascular, INC. | $146.86 | 2019-2020 | |
| Abbott Laboratories | $134.17 | 2020-2025 | Navitor, Perclose Proglide |
| Amgen INC. | $121.53 | 2019-2025 | Repatha |
| Irhythm Technologies, INC. | $99.05 | 2024 | Zio Monitor, Zio Xt Patch |
| Philips North America LLC | $48.80 | 2024 | (Cm9) Amb Mon & Diag Und |
| Merck Sharp & Dohme LLC | $42.71 | 2024-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $38.90 | 2019-2025 | Wainua |
| Janssen Pharmaceuticals, INC | $37.82 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $36.66 | 2019 | |
| Penumbra, INC. | $36.48 | 2025 | Indigo System |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $36.37 | 2025 | |
| Cardiovascular Systems INC. | $28.07 | 2019-2021 | |
| Boston Scientific Corporation | $27.99 | 2022-2025 | Cds - Mct/Cem Monitoring |
| Sanofi-Aventis U.S. LLC | $20.29 | 2019 | |
| Elutia, INC. | $6.90 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$264,736.48 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Mayes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.